Recent advances in
chemicals
clinical trials
ex vivo
expansion
human hematopoietic stem cell
polymers
Journal
Blood cell therapy
ISSN: 2432-7026
Titre abrégé: Blood Cell Ther
Pays: Japan
ID NLM: 9918333884906676
Informations de publication
Date de publication:
25 Nov 2023
25 Nov 2023
Historique:
received:
05
09
2023
accepted:
02
10
2023
medline:
27
12
2023
pubmed:
27
12
2023
entrez:
27
12
2023
Statut:
epublish
Résumé
Hematopoietic stem cells (HSCs) are a rare cell population present in the bone marrow. They possess self-renewal and multipotent differentiation capacities and play a crucial role in lifelong hematopoiesis and reconstitution of the hematopoietic system after hematopoietic stem cell transplantation (HSCT). HSCT remains the only curative treatment for refractory hematologic disorders. Umbilical cord blood (CB) has several advantages as an alternative donor for HSCT, including HLA flexibility and lack of donor burden. However, CB has limitations in terms of cell dose, restricted donor options, and prolonged time to engraftment. Development of techniques for expanding HSCs
Identifiants
pubmed: 38149022
doi: 10.31547/bct-2023-026
pmc: PMC10749727
doi:
Types de publication
Journal Article
Langues
eng
Pagination
151-157Informations de copyright
Copyright Ⓒ2023 Asia-Pacific Blood and Marrow Transplantation Group (APBMT).
Déclaration de conflit d'intérêts
M.S. is co-founder and shareholder in Celaid Therapeutics. Disclosure form provided by the author is available on the website.